Skip to content
BALCAO · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Vycor Medical Inc. VYCO

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$1.9M
▲ 17.2% YoY
$-72,426
$-18,695
▼ 134.1% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Vycor Medical designs, develops and markets medical devices for use in neurosurgery. NovaVision provides non-invasive rehabilitation therapies for those who have vision disorders resulting from neurological brain damage such as that caused by a stroke. Vycor Medical’s ViewSite Brain Access System (“VBAS”) is a next generation retraction and access system. Vycor Medical is ISO 13485:2016 and MDSAP (Medical Device Single Audit Program) certified, and VBAS has U.S. FDA 510(k) clearance and CE Marking for Europe (MDD Class III) for brain and spine surgeries, and regulatory approvals in other international markets. NovaVision provides non-invasive, computer-based rehabilitation therapies targeted at people who have impaired vision as a result of stroke or other brain injury. We currently have 7 employees.

Written from the business description in VYCOR MEDICAL INC's annual report to the U.S. Securities and Exchange Commission, filed 31 March 2026. Every sentence was checked against that document before publication.

Growth

USD 1.9M
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 1.9 · Net income -0.1
1M2M-2M-4M
201020132016201920222025
Compound annual growth
+15.1%
+10.3%
+5.0%
+12.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +10.3% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−4 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating 1.8% · Net -3.9%
-200%-400%-600%
201020172025
ROE
FY2015 · ROE -103.2%
-1000%-2000%
201020172025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -0.0
-2M-3M
201020172025

Total assetsUSD 830,420.00
EquityUSD -4.1M
CashUSD 86,982.00
Current ratio0.12×

Equity funds -492% of total assets.

The 16-year record

16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
VYCO, 16-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.00.00.00.00.00.00.00.00.00.00.0◌0.00.00.00.0
Operating income $B0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌−0.0−0.0−0.0−0.0
EBITDA $B0.00.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax €B◌◌◌◌◌◌◌◌◌◌0.00.0◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌−0.0−0.0−0.0−0.0
Free cash flow $B−0.00.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.01−0.01−0.01−0.02−0.03−0.04−0.05−0.08−0.10−0.17−0.20−0.39−0.39−0.52−0.92−0.00
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————————————
ROE %——————————−103.2———−991.4−2236.2
Shares out B0.030.030.030.030.030.030.030.020.020.010.010.010.010.010.010.72

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 3 failures in 79 reconciliationsAUDITED

Reconciled in 13 of the 16 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Four checks were skipped: the share count is not tagged before 2011. Three checks were skipped: revenue is not tagged before 2010.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency3 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image